Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Science Daily

Stem cell pain sponge soaks up osteoarthritis joint pain and protects cartilage

SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic ...

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Open Access Government

The next step in regenerative medicine for osteoarthritis: Spscs and a new regulatory pathway

Osteoarthritis (OA) remains one of the leading causes of disability worldwide, burdening health systems and diminishing quality of life ...
European Medical Journal

Treating Diabetic Foot Ulcers with Stem Cells and Growth Factors

Stem cells and growth factors are effective at treating diabetic foot ulcers. Improved treatment protocols required for clinical adoption.
Smithsonian Magazine

A New Way to Boost the Powerhouses of the Cell Might Combat Aging and Degenerative Diseases, Lab Study Suggests

Creating mini mitochondria factories helped recharge damaged cells in a dish, providing proof-of-concept work that could pave ...

B cells temporarily regain stem-like flexibility, increasing risk of lymphoma formation

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...